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Abstract Scintillation proximity assay (SPA) is a radio-
isotopic technology format used to measure a wide range of
biological interactions, including drug-target binding affinity
studies. The assay is homogeneous in nature, as it relies on a
Bmix and measure^ format. It does not involve a filtration step
to separate bound from free ligand as is the case in a traditional
receptor-binding assay. For G protein-coupled receptors
(GPCRs), it has been shown that optimal binding kinetics,
next to a high affinity of a ligand, can result in more desirable
pharmacological profiles. However, traditional techniques to
assess kinetic parameters tend to be cumbersome and labori-
ous. We thus aimed to evaluate whether SPA can be an alter-
native platform for real-time receptor-binding kinetic mea-
surements on GPCRs. To do so, we first validated the SPA
technology for equilibrium binding studies on a prototypic
class A GPCR, the human adenosine A1 receptor (hA1R).
Differently to classic kinetic studies, the SPA technology
allowed us to study binding kinetic processes almost real time,
which is impossible in the filtration assay. To demonstrate the
reliability of this technology for kinetic purposes, we per-
formed the so-called competition association experiments.
The association and dissociation rate constants (kon and koff)
of unlabeled hA1R ligands were reliably and quickly deter-
mined and agreed very well with the same parameters from a
traditional filtration assay performed simultaneously. In con-
clusion, SPA is a very promising technique to determine the
kinetic profile of the drug-target interaction. Its robustness and
potential for high-throughput may render this technology a
preferred choice for further kinetic studies.
Keywords Gprotein-coupled receptors . Scintillation
proximity assay . Binding kinetics . Adenosine A1 receptor .
Residence time
Introduction
Scintillation proximity assays (SPA) are a bead-based assay
technology for radioligand binding studies in drug research [1,
2]. The technology is homogeneous in nature, as it relies on a
Bmix and measure^ format and avoids a filtration step to sep-
arate bound from unbound radiolabeled ligand as is the case in
a traditional receptor-binding assay [3]. SPA technology,
therefore, allows the rapid and convenient assay of a wide
range of molecular interactions in a homogeneous system [4,
5]. With the help of a suitable radiolabeled probe, the affinity
of a compound for its drug target, such as G protein-coupled
receptors (GPCRs), can be determined fast and reliably by
SPA technology [6–9]. Nowadays in industry, SPA technolo-
gy is routinely used for radioligand binding assays to deter-
mine ligand affinity in drug screening applications where
high-throughput is required [10].
Alongside classical affinity parameters such as IC50 and Ki
values, drug-target binding kinetics, in particular, the receptor-
ligand residence time (RT) is emerging as an additional pa-
rameter to assess the therapeutic potential of drug candidates
with respect to drug efficacy and safety [11–14].
Consequently, there is an increasing awareness of the impor-
tance of measuring the kinetics of drug-target interactions. In
the research field of GPCRs, a number of structure-kinetic
relationship (SKR) studies have been published that suggest
that for educated compound triage for further studies binding
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kinetics should be included in the decision process [15–17].
Therefore, a fast and trustful approach to determine kinetic
parameters is urgently required.
By definition, the RT is inversely proportional to the ligand
dissociation rate constant (koff). This rate constant together
with the association-rate constant (kon) can both be retrieved
from appropriate kinetic experiments following the principles
laid out by Motulsky and Mahan [18]. In that publication, so-
called competition association experiments are described,
which are conventionally performed in the form of filtration
assays. In this format, the method consumes a great amount of
radioligand, membrane protein, and other materials. Besides,
the tediousness and limited throughput of the kinetic assay are
impediments to obtain kon and koff values for series of ligands
efficiently.
So far, there have been quite a few attempts to improve the
efficiency of kinetic screening. For example, an insurmount-
able effect of slowly dissociating ligands in a functional IP-1
assay in SPA format on the neurokinin-1 (NK1) receptor has
been described [19]. In this case, the costly functional meth-
odology only allowed for the qualitative screening of the
slowly dissociating ligands. Another kinetic screening ap-
proach in the form of SPA technology took the observation
of a Ki (leftward) shift [20] over time as proof for slowly
dissociating compounds from different GPCRs [6, 7].
Although SPA technology was used in both studies,
they were essentially equilibrium binding assays with
long incubation times (10 h in gonadotropin-releasing
hormone (GnRH) receptor [6] and 5 h in human
CCR5 receptor [7]).
Recently, a method called dual-point competition associa-
tion assay that enables the relatively fast kinetic screening of
series of compounds was introduced by Guo et al. [21]. By
measuring radioligand binding at two different time points in
the absence or presence of unlabeled competitors, the kinetic
rate index (KRI) was obtained. Although both fast and slowly
dissociating ligands can be characterized and discriminated
with this index, it is still a rather qualitative measure, as the
kon (k3) and koff (k4) values of the unlabeled ligands cannot be
obtained. Thus, the resolution of a kinetic comparison for
SKR through KRI values is not as high as with full kinetic
parameters [17].
The true benefit of SPA technology relies in its separation-
free approach, which could allow almost continuous kinetic
measurements over time. Previously, a kinetic study of
radioligand association and dissociation by SPA technology
has been reported for the inositol trisphosphate receptor
(InsP3R), a Ca
2+ channel, and it indeed confirmed that SPA
is a useful technique to determine fast kon and koff values that
might have been difficult to obtain using traditional methods
[22]. However, SPA technology as a format to study the ki-
netics of radioligand binding to GPCRs has not been reported
in any detail.
Therefore, in the present study, we aimed to fill this gap by
converting a filtration-based kinetic radioligand binding assay
to an SPA format, using a prototypical GPCR, the human
adenosine A1 receptor (hA1R), as an example. We firstly val-
idated the SPA technology for equilibrium binding studies by
comparing it to traditional filtration assays performed simul-
taneously. In these experiments, both hA1R agonists and an-
tagonists were tested, and their affinity determined with SPA
technologywas similar to the affinity determined in a filtration
assay. In subsequent kinetic studies, the SPA technology was
of great benefit, as it allowed us to follow radioligand binding
over time in a single well, which is impossible in the filtration
assay. We further demonstrated advantage in the most labori-
ous of all kinetic assays, the competition association experi-
ment. The association and dissociation rate constants of unla-
beled ligands for hA1R were reliably and quickly determined
and agreed very well with the same parameters in a traditional
filtration assay performed in parallel.
Materials and methods
Chemicals and reagents
[3H]-1,3-Dipropyl-8-cyclopentyl-xanthine ([3H]-DPCPX,
specific activity 113.4 Ci ·mmol−1) was purchased from
ARC, Inc. (St. Louis, MO). The Wheat Germ Agglutinin-
Polyvinyl toluene (WGA-PVT) SPA beads (RPNQ0001)
were purchased from PerkinElmer (Waltham, MA).
Adenosine deaminase (ADA) was purchased from
Boehringer Mannheim (Mannheim, Germany). 1,3-
Dipropyl-8-cyclopentyl-xanthine (DPCPX, a selective hA1R
an tagon i s t [23 ] ) , 8 - cyc lopen ty l -3 -N - [ 3 - ( (3 - ( 4 -
fluorosulphonyl)benzoyl)-oxy)-propyl]-1-N-propyl-xanthine
(FSCPX, an irreversible hA1R antagonist [24]), 2-chloro-N
6-
cyclopentyladenosine (CCPA, a selective hA1R agonist [25]),
N6-cyclopentyladenosine (CPA, a selective hA1R agonist
[25]), 5′-N-ethylcarboxamidoadenosine (NECA, a non-
selective agonist for adenosine receptors [26]), and guano-
sine-5′-triphosphate (GTP) were purchased from Sigma (St.
Louis, MO). BCA (bicinchoninic acid) protein assay kit was
obtained from Pierce Chemical Company (Rockford, IL).
LUF5834 (an hA1R partial agonist) was synthesized in our
laboratory as described previously [27]. Chinese hamster ova-
ry (CHO) cells stably expressing the hA1R were obtained
from Prof. Steve Hill (University of Nottingham, UK). All
other chemicals were of analytical grade and obtained from
standard commercial sources.
Cell culture and membrane preparation
CHO cells stably expressing hA1R were grown in Ham’s F12
medium containing 10 % (v·v−1) normal adult bovine serum,
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streptomycin (100 μg·mL−1), penicillin (100 IU·mL−1), and
G418 (0.4 mg·mL−1) at 37 °C in 5 % CO2. Cells were
subcultured twice weekly at a ratio of 1:20 on 10-cm ø culture
plates. For membrane preparation, cells were subcultured 1:10
and then transferred to 15-cm ø plates. Cells grown to 80 to
90 % confluency were detached from plates by scraping them
into 5 mL phosphate-buffered saline (PBS), collected, and
centrifuged at 700 g (3 000 rpm) for 5 min. Cell pellets derived
from 30 plates were pooled and resuspended in 20 mL of ice-
cold 25 mM Tris-HCl buffer (pH 7.4). An UltraThurrax
(Heidolph Instruments, Schwabach, Germany) was used to
homogenize the cell suspension.Membranes and the cytosolic
fraction were separated by centrifugation at 100,000g (31
000 rpm) in a Beckman Optima LE-80K ultracentrifuge
(Beckman Coulter, Fullerton, CA) at 4 °C for 20 min. The
pellet was resuspended in 15 mL of the Tris-HCl buffer, and
the homogenization and centrifugation step was repeated.
Tris-HCl buffer (10 mL, pH 7.4) was used to resuspend the
pellet, and ADA was added (0.8 IU·mL−1) to break down
endogenous adenosine. Membranes were stored in 250 μL
aliquots at −80 °C. Concentrations of membrane protein were
measured using the BCA method [28].
Radioligand displacement experiments
The displacement experiments were performed using 10 con-
centrations of competing ligands in 25 μL of assay buffer (For
antagonists: 50 mM Tris-HCl [pH 7.4 at 25 °C]; for agonists:
50 mM Tris-HCl supplemented with 5 mM MgCl2 [pH 7.4])
in the presence of another 25 μL of assay buffer with a final
concentration of 2.4 nM [3H]-DPCPX. At this concentration,
total radioligand binding did not exceed 10 % of that added to
prevent ligand depletion. Non-specific binding (NSB) was
determined in the presence of 100 μM CPA. Each condition
was measured in duplicate, and at least three individual exper-
iments were performed.
The SPA technology A mixture of 5 μg protein membrane
and 1 mg SPA bead was pre-coupled in a shaker (Vibrax
VXR, IKA) in a volume of 50 μL of assay buffer at room
temperature for 30 min. Then, together with the radioligand
and competing ligands, the membrane-bead mixture was
dispatched in an Isoplate-96 Microplate (Perkin Elmer,
Groningen, the Netherlands), in a final reaction volume of
100 μL. The plate was incubated for 1 h inside the counting
chamber of a 2450 MicroBeta2 Plate Counter (Perkin Elmer,
Groningen, the Netherlands) at the ambient temperature of
28 °C. The binding values were recorded in corrected counts
per minute (CCPM).
The filtration assayMembrane aliquots containing 5 μg pro-
tein were incubated together with the radioligand and compet-
ing ligands in a total volume of 100 μL assay buffer in a 96-
well plate. After 1 h incubation at room temperature, the in-
cubation was terminated by rapid vacuum filtration to separate
the bound and free radioligand through 96-well GF/B filter
plates using a PerkinElmer Filtermate-harvester (Perkin
Elmer, Groningen, the Netherlands). Filters were subsequent-
ly washed three times with ice-cold wash buffer (50 mM Tris-
HCl [pH 7.4], supplemented with 5 mMMgCl2). After 30min
of dehydration of the filter plate at 50 °C, the filter-bound
radioactivity was determined by scintillation spectrometry
using the 2450 MicroBeta2 Plate Counter. The binding values
were recorded in both counts per minute (CPM) and disinte-
grations per minute (DPM).
Radioligand association and dissociation experiments
The SPA technology The membrane-bead mixture was pre-
pared as described under BRadioligand displacement
experiments.^ Once the membrane-bead mixture was added
to the wells of an Isoplate-96 Microplate, measurements of
radioligand bound to the receptor were started immediately
and continued every 30 s for 1 h, using the 2450 MicroBeta2
Plate Counter. Subsequently, radioligand dissociation was ini-
tiated by the addition of 10μMunlabeled CPA. Another 1 h of
measurements at every 30 s was used to record the amount of
radioligand still bound to the receptor. Samples were obtained
as described under BRadioligand displacement experiments.^
The filtration assayAssociation experiments were performed
by incubating membrane aliquots containing 5 μg of protein
in a total volume of 100 μL of assay buffer at 28 °C with
2.4 nM [3H]-DPCPX. The amount of radioligand bound to
the receptor was measured at different time intervals during
a total incubation of 1 h. Dissociation experiments were per-
formed by preincubating membrane aliquots containing 5 μg
of protein in a total volume of 100 μL of assay buffer for 1 h.
After the preincubation, radioligand dissociation was initiated
by the addition of 10 μM unlabeled CPA. The amount of
radioligand still bound to the receptor was measured at various
time intervals for a total of 1 h to ensure that full dissociation
from hA1R was reached. Incubations were terminated, and
samples were obtained as described under BRadioligand dis-
placement experiments.^
Competition association experiments
The binding kinetics of unlabeled ligands was quantified
using the competition association assay based on the theoret-
ical framework by Motulsky and Mahan [18]. In this experi-
ment, one concentration of IC50 or three different concentra-
tions of unlabeled competing ligands were tested—namely, at
IC25, IC50, and IC75 determined from BRadioligand displace-
ment experiments.^ For (partial) agonists, 1 mM of GTP was
present in the agonist assay buffer to ensure that agonist
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binding only occurred to the uncoupled form of hA1R [13].
The assay was performed by incubating in a total volume of
100 μL of assay buffer at 28 °C with 2.4 nM [3H]-DPCPX.
The SPA technology The membrane-bead mixture was pre-
pared as described under BRadioligand displacement
experiments.^ Once the membrane-bead mixture was added
to the wells of an Isoplate-96 Microplate, measurements of
radioligand bound to the receptor were started immediately
and continued every 30 s for 2 h, using the 2450 MicroBeta2
Plate Counter. Samples were obtained as described under
BRadioligand displacement experiments.^
The filtration assay The competition association assay was
initiated by adding membrane aliquots (5 μg per well) at dif-
ferent time points for a total of 2 h in the absence or presence
of competing ligand. Incubations were terminated and sam-
ples were obtained as described under BRadioligand displace-
ment experiments.^
Data analysis
All values obtained are means of at least three independent
experiments performed in duplicate. All experimental data
were analyzed by using GraphPad Prism 6 (GraphPad
Software, Inc., San Diego, CA), as in the description of pre-
vious work from our research group [21], including the fol-
lowing analysis: IC50 values obtained from competition dis-
placement binding data were converted to Ki values using the
Cheng-Prusoff equation [29], the kon and koff values for
radiolabeled and unlabeled ligands were fitted and calculated,
and the kon and koff values were used to calculate residence
times (in min) and kinetic dissociation binding constants (ki-
netic KD).
Results
The affinity (Ki) of hA1R ligands in displacement
experiments
The affinities of several hA1R ligands were determined by
displacement experiments formatted with SPA technology or
as filtration assays. The tested hA1R ligands showed
concentration-dependent inhibition of specific [3H]-DPCPX
binding, and the data of antagonists (DPCPX, FSCPX) or
partial agonist (LUF5834) were best fitted to a one-state com-
petition model, while the data of full agonists (CCPA, NECA)
were best fitted with a two-state receptor model. Affinities of
all ligands determined by both SPA technology and filtration
assay are shown in Table 1. All compounds showed high
affinities, with those of antagonists and partial agonist in the
nanomolar range. The agonists displayed high, nanomolar
affinity for the so-called high affinity state, and lower,
submicromolar affinity for the low affinity state. The affinities
of the hA1R ligands from these equilibrium experiments were
in good agreement between SPA technology and filtration
assay (Fig. 1). Due to the irreversible binding characteristics
of FSCPX, only its Bapparent^ affinity could be determined,
which was subsequently included in the correlation.
The association (kon) and dissociation rate constants (koff)
of [3H]-DPCPX at hA1R
Receptor association and dissociation rates of [3H]-DPCPX
were directly determined in classic radioligand association
and dissociation experiments with either SPA technology or
filtration assays. In both assay formats, the binding of [3H]-
DPCPX approached equilibrium after approximately 15 min
Table 1 Comparison of the affinity of representative hA1R antagonists
and (partial) agonists obtained from displacement studies of specific [3H]-
DPCPX binding from hA1R membranes by SPA technology or filtration
assay, respectively. Values are means±s.e.m of at least three independent
experiments performed in duplicate. For full agonists CCPA and NECA,
displacement curves were best analyzed with a two-state model, yielding
Ki values for a high affinity state and a low affinity state of the receptor
Compound SPA Ki (nM) Filtration Ki (nM)
FSCPX 0.9±0.02a 1.6±0.1a
DPCPX 4.3±0.4 3.3±0.3
LUF5834 6.2±0.5 4.3±0.6
CCPA 7.0±1.1 (high) 8.3±3.8 (high)
861±156 (low) 1010±159 (low)
NECA 8.0±2.3 (high) 7.8±3.8 (high)
282±80 (low) 301±39 (low)
a BApparent^ affinity of this irreversibly binding antagonist
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(Fig. 2), indicating a relative fast kon of 0.40±0.05 nM
−1·
min−1 by SPA technology and 0.24±0.03 nM−1·min−1 by fil-
tration. Binding of the radioligand was reversible after the
addition of 10 μM CPA, and complete dissociation was
reached after approximately 25 min (Fig. 2). The koff of
[3H]-DPCPX from the hA1R was 0.20±0.02 min
−1 with
SPA technology and 0.25±0.01 min−1 in the filtration assay
(Table 2). The kinetic KD (koff/kon) of [
3H]-DPCPXwas 0.50±
0.08 nM (SPA) and 1.04±0.14 nM (filtration) (Table 2). The
residence time (RT, 1/koff) of [
3H]-DPCPX was calculated as
5.0±0.5 or 4.0±0.2 min, determined by SPA or filtration,
respectively.
The competition association assay at hA1R
With the established kon (k1) and koff (k2) values of [
3H]-
DPCPX binding from classic association and dissociation ex-
periments, kon (k3) and koff (k4) values of unlabeled DPCPX
were determined by fitting the values based on the
mathematical model as previously described (see Materials
and methods). Three different concentrations of unlabeled
DPCPX, lower than (IC25), equal to and higher than (IC75)
its IC50 value, were tested (Fig. 3). Its kon and koff values
determined by this competition association method were
0.72±0.16 nM−1 ·min−1 and 0.50±0.01 min−1 by SPA
(Fig. 3a and Table 3) or 0.19±0. 04 nM−1·min−1 and 0.27±
0.03 min−1 by filtration (Fig. 3b and Table 3), which were in
good accordance with the k1 and k2 values determined in the
classic association and dissociation experiments (Table 2 and
Fig. 2). Since the kineticKD values and affinities (Ki) obtained
from the different equilibrium and kinetic experiments are
well comparable (Tables 1, 2, and 3), this further verified that
the competition association assay by SPA technology could be
accurately used to determine the binding kinetics of unlabeled
A1R ligands.
We then used FSCPX, an irreversibly binding hA1R antag-
onist, as a further validation tool. In the competition associa-
tion assay, FSCPX displayed an Bovershoot^ in the associa-
tion curve indicating a negligible dissociation, which was ob-
served in both SPA (Fig. 4a) and filtration assay (Fig. 4b). Its
kon and koff values determined by the competition association
method were 0.0047±0.0007 nM−1 ·min−1 and 0.0064±
0.0013 min−1 by SPA or 0.0019±0.0003 nM−1·min−1 and
0.0060±0.0020 min−1 by filtration (Table 3).
The other unlabeled ligands included the hA1R partial ag-
onist LUF5834 and full agonists CCPA and NECA. Their kon
and koff values were determined in both SPA and filtration
assays, in the presence of 1 mM GTP (Figs. 5, 6, and 7 and
Table 3). The current mathematical model does not allow the
calculation of two receptor states with corresponding kinetic
parameters; the inclusion of GTP in the assay forces the re-
ceptor to be in one lower affinity, G protein-uncoupled state
only. With this restriction, the kinetic parameters of both par-
tial and full agonists were determined as conveniently as the
two antagonists (Table 3). The kinetic profiles (kon and koff) of
all hA1R ligands obtained by SPA were in good agreement
with the results from filtration (Fig. 8a, b). Due to its irrevers-
ible binding nature, FSCPX was not included in the correla-
tion. The correlation between kinetic KD values from either
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Fig. 2 Association and dissociation kinetics of [3H]-DPCPX (2.4 nM) to
and from hA1R stably expressed on CHO cell membranes (28 °C),
measured in SPA technology (n=3, combined and normalized, a) or
filtration assay (n=3, combined and normalized, b). 10 μM CPA was
used as a displacer to initiate the dissociation. Association data was
fitted in Prism 6 using one-phase exponential association. Dissociation
data was fitted using one-phase exponential decay
Table 2 Comparison of the kinetic rates of [3H]-DPCPX obtained from
classic kinetic association and dissociation experiments from hA1R
membranes at 28 °C by SPA assay and filtration assay. Values are
means±s.e.m of three independent experiments performed in duplicate.
Equations used are as follows: kon=(kobs−koff)/[[3H]-DPCPX]; Kinetic
KD=koff/kon; RT=1/koff. RT is residence time
[3H]-DPCPX SPA Filtration
kon (nM
−1·min−1) 0.40±0.05 0.24±0.03
koff (min
−1) 0.20±0.02 0.25±0.01
Kinetic KD (nM) 0.50±0.08 1.0±0.1
RT (min) 5.0±0.5 4.0±0.2
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SPA or filtration assay was high too (Fig. 8c). Finally, with
data from all experiments at hand, we concluded that the equi-
librium Ki and kinetic KD values from both SPA technology
and filtration assay were also highly correlated (Fig. 8d, e).
Discussion
In this study, we developed and validated a method based on
the principles of a scintillation proximity assay (SPA) for the
determination of kinetic characteristics of GPCR ligands. The
adenosine A1 receptor was used as our workhorse, together
with a number of reference ligands with divergent character-
istics. In the following, we discuss the benefits and relatively
minor concerns of the approach.
Advantages of SPA technology
We substituted a standard filtration assay by SPA technology
to determine the kinetics of the drug-receptor interaction. In
that setting, the most obvious improvement is that the event of
ligand association and dissociation to and from the receptor
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Fig. 3 Competition association
experiments with [3H]-DPCPX
binding to hA1R stably expressed
on CHO cell membranes (28 °C)
in the absence or presence of 1.5,
4.5, and 14 nM of unlabeled
DPCPX by SPA assay (n=4,
combined and normalized, a) or
classic filtration assay (n=3,
combined and normalized, b)
Table 3 Comparison of the kinetic rate constants, residence times (RT)
and kinetic KD values of representative hA1R antagonists and (partial)
agonists obtained from competition association experiments to hA1R
expressed on CHO cell membranes at 28 °C by SPA assay and
filtration assay. For (partial) agonists LUF5834, CCPA, and NECA,
1 mM GTP was present in the assay. The kon (k3), koff (k4) values of the
unlabeled compounds were determined in [3H]-DPCPX (2.4 nM)
competition association experiments. RTs and kinetic KDs were
determined in the same manner as described in Table 2
Cmpd. SPA Filtration assay
kon (nM
−1·min−1) koff (min
−1) RT (min) Kinetic KD (nM) kon (nM
−1·min−1) koff (min
−1) RT (min) Kinetic KD (nM)
FSCPX 0.0047±0.0007 0.0064±0.0013 156±31 1.4±0.3 0.0019±0.0003 0.0060±0.0020 167±56 3.2±0.4
DPCPX 0.72±0.16 0.50±0.01 2.0±0.1 0.69±0.15 0.19±0. 04 0.27±0.03 3.7±0.4 1.4±0.1
LUF5834 0.13±0.05 0.50±0.05 2.0±0.1 3.9±1.5 0.062±0.006 0.23±0.03 4.4±0.5 3.7±0.5
CCPA 0.0094±0.0022 0.73±0.04 1.4±0.1 78±19 0.016±0.002 1.5±0.03 0.68±0.01 92±9
NECA 0.0014±0.0004 0.54±0.06 1.9±0.02 386±36 0.0012±0.0001 0.60±0.04 1.7±0.1 500±8
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Fig. 4 Competition association
experiments with [3H]-DPCPX
binding to hA1R stably expressed
on CHO cell membranes (28 °C)
in the absence or presence of
25 nM FSCPX, measured in
SPA technology (n=4,
combined and normalized, a)
or filtration assay (n=3,
combined and normalized, b)
0
200
400
600
800
1000
1200
1400
1600
1800
2000
2200
2400
a
b
[3
H
] 
D
P
C
P
X
 B
in
d
in
g
 (
C
C
P
M
)
ctrl + 1m MGTP
+ 8 nM LUF5834 + 1 mM GTP
+ 75 nM LUF5834 + 1 mM GTP
+ 25 nM LUF5834 + 1 mM GTP
ctrl + 1m MGTP
+ 8 nM LUF5834 + 1 mM GTP
+ 75 nM LUF5834 + 1 mM GTP
+ 25 nM LUF5834 + 1 mM GTP
0
20
40
60
80
100
120
[3
H
] 
D
P
C
P
X
 B
in
d
in
g
 %
0 20 40 60 80 100 120
Time (min)
0 20 40 60 80 100 120
Time (min)
Fig. 5 Competition association
experiments with [3H]-DPCPX
binding to hA1R stably expressed
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can be measured almost in real time without washing steps
which are indispensable in a filtration assay. This improve-
ment brings the benefit of great efficiency in kinetic
radioligand binding experiments. For example, in the filtration
format, association and dissociation kinetics of [3H]-DPCPX
to and from hA1R are determined separately, because it is
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impractical to perform both association and dissociation ex-
periments in one 96-well plate. However, in the SPA format,
only a single well is required to record such a full curve
(Fig. 2). This also brings impressively improved
throughput in the competition association assay of unla-
beled ligands with [3H]-DPCPX as the radioligand. In
an individual filtration experiment, to measure competi-
tion association, a whole 96-well plate is used, allowing
for two duplicate curves from three different concentra-
tions of unlabeled ligand and a control curve. However,
with SPA, only a few wells are required to obtain the
same results, as is shown in Figs. 3, 4, 5, 6, and 7. This
is due to the six-detector panel operating simultaneously
in the counter, allowing a rich data collection of six
wells simultaneously. On average, the duration of an
n=3 competition association experiment by SPA is
reduced to 1–2 days from almost 1 week of practical
work by filtration, with the additional benefit of much
less bench time.
The SPA technology not only improved the speed and
throughput of the kinetic radioligand binding experiments
but also provided more, more precise and more accurate data.
The competition association experiment is based on the
Motulsky-Mahan model for competition association, which
requires a substantial number of data points for plotting curves
and subsequent analysis. In other words, the more data points
obtained, the more accurate kon and koff can be determined.
The SPA technology enables to acquire a great number (more)
of data points, from one well rather than separate tubes (more
precise). In this case of a 2-h experiment, one well on a 96-
well plate was sampled every 30 s, yielding a total of 240 data
points in one curve, while in the comparable filtration assay,
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there are only a labor-intensive dozen or so (Figs. 3, 4, 5, 6,
and 7). A further reason of concern in the filtration assay is
that the separation step only differentiates bound from un-
bound ligand, irrespective of whether the binding process it-
self consists of several steps [7] or that weaker interactions are
broken such that only a fraction of receptor-ligand complexes
might be detected after washing [30]. In the absence of filtra-
tion steps, SPA technology provides the possibility to collect
this information without these caveats (more accurate). Lastly,
overall financial expenses are favorable. Although the beads
come at a price, the hugely reduced number of wells makes the
experiment very cost-effective.
Differences in SPA technology from filtration assay
SPA is a homogeneous bead-based technique, in which the
receptor membrane protein is coupled with a certain type of
SPA bead. Although there are several approaches to add SPA
beads to the reaction (such as a precoupled format, a simulta-
neous addition (BT=0^) format, or delayed addition format
[10]), for kinetic experiments, precoupling of the cell mem-
branes with SPA beads is necessary. The convenience of doing
so is that bead and membrane are treated as a single reagent,
thus reducing the time to dispense an assay, and there is no
issue of membrane-bead diffusion. More importantly, the
membrane-bead ratio needs to be optimized to generate a use-
ful specific radioligand binding Bwindow.^ In our case, 5 μg
of hA1R membrane protein was associated with 1 mg of
WGA-PVT beads. Adding an excess of SPA beads would
ensure that all the membranes are captured and a maximum
signal is obtained, but the excess might equally contribute to
an increased background signal [1]. It should be realized that
besides normal non-specific binding (NSB), another back-
ground signal called non-proximity effect (NPE) may play a
role. This was clearly observed in kinetic assays. The NPE is
to describe that if a radioligand stays in close proximity, the
bead would be activated irrespective of whether the
radioligand is bound to the bead or membrane-bead mixture
[2]. From Fig. 2a, it seems that [3H]-DPCPX did not fully
dissociate from the hA1R as was the case in the filtration assay
(Fig. 2b), with an elevated baseline of approx. 10 % of
radioligand binding. This observation does not necessarily
mean there was still 10 % of [3H]-DPCPX binding to the
hA1R but rather indicates that some of the liberated [
3H]-
DPCPX stayed in the proximity of the bead, yielding
a weak signal.
In the SPA technology, there is no need to add liquid scin-
tillation fluid after harvesting as in filtration assays. As a con-
sequence, the typical CPM-DPM conversion from the spec-
trometer’s counting efficiency as a result of quenching cannot
be done [31–33]. As all events take place at the surface of the
SPA bead [2], the light-emitting process cannot be quenched.
A further different and unique aspect of SPA technology and
corresponding equipment is that samples are monitored from
both top and bottom and a count is only a count when top and
bottom detectors both record the light quant within a certain
amount of time. It is possible that a light quant is emitted at the
top of the well by dispersion by the beads, while this quant is
not seen by the bottom detector. The counter has the possibil-
ity to make a correction for this and therefore the CPM mea-
sured with SPA is referred to as CCPM which stands for
Bcorrected^ CPM (the x-axis of Figs. 5a, 6a, and 7a) [33].
Challenges for SPA technology
Despite the many benefits of using SPA technology, there are
also challenges in SPA radioligand binding studies. As men-
tioned above, the higher background signal of SPA consists of
NSB and/or NPE. The NPE can be reduced by centrifuging
the beads or allowing them to settle prior to counting, and by
increasing the volume of the assay, but all these work-around
solutions are either not feasible or impractical in kinetic
radioligand binding experiments.
Secondly, although not much of an issue in our current
experiments, the window of specific binding may need further
consideration. Along this vein, one may try different SPA
beads. There are two basic types of SPA beads: one is com-
posed of plastic-based polyvinyltoluene (PVT), the other is
silica-based yttrium silicate (Ysi). In general, PVT beads are
bigger in size, in a regular ball shape, but lighter, while Ysi
beads are crystal amorphous solids, which are heavier [2, 10].
Although in our case of the hA1R we chose the PVT beads, it
was recently reported that two types of Ysi beads were used
for radioligand binding studies on the adenosine A2A receptor
[34, 35]. Apart from the abovementioned beads designed for
photomultiplier tube/well-based counters, there is another
type of yttrium-based beads optimized for sensitive imaging-
based detectors, the red-shifted yttrium oxide (YO) SPA bead.
Both Ysi and YO SPA beads have been reported to enable
HTS and to improve on the filtration method [36, 37].
Thirdly, even in a fast operation, the first 30 s of ligand
association or dissociation cannot be recorded, as it takes time
to have the spectrometer place the detectors above the wells
and measure scintillations [7]. This is not an issue in our case
of the hA1R, but it can be crucial with fastly associating li-
gands. This could be improved by using an automatic injec-
tion module inside the counter, although this is currently not
provided. Lastly, the temperature inside the counting chamber
is fixed and slightly higher than room temperature (in our
experiments, the temperature was 28±1 °C). In a typical fil-
tration assay, kinetic radioligand binding experiments can be
performed at lower or higher temperatures according to the
characteristics of the radioligand—target interaction.
Although in some scintillation counters it is possible to adjust
temperature from 19 to 35 °C [34], a broader choice of assay
temperatures would be highly advantageous.
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Conclusion
We reported a rapid and reliable technique, the scintillation
proximity assay (SPA) technology, for kinetic radioligand bind-
ing studies on a prototypic GPCR, the human adenosine A1
receptor (hA1R). The SPA technology was of great benefit, as
it monitored the event of radioligand binding in a single well in
almost real time, which is impossible in traditional filtration
assays. Even in the otherwise most laborious of all kinetic as-
says, the competition association assay, the kinetic profiles (kon
and koff) of unlabeled ligands for the hA1R were reliably and
quickly determined and agreed very well with the same param-
eters in a filtration assay performed simultaneously. In conclu-
sion, SPA is a very promising technique to determine the kinetic
profiles of the drug-target interaction in the early phase of drug
discovery. Its robustness and potential high-throughputmay ren-
der this technology a preferred choice for further kinetic studies.
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